<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39692336</PMID><DateCompleted><Year>2024</Year><Month>12</Month><Day>18</Day></DateCompleted><DateRevised><Year>2024</Year><Month>12</Month><Day>18</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2173-9110</ISSN><JournalIssue CitedMedium="Internet"><Volume>98</Volume><PubDate><Year>2024</Year><Month>Dec</Month><Day>18</Day></PubDate></JournalIssue><Title>Revista espanola de salud publica</Title><ISOAbbreviation>Rev Esp Salud Publica</ISOAbbreviation></Journal><ArticleTitle>[Evaluation of hepatitis B vaccination in newborns at high risk of infection by vertical transmission].</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">e202412065</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Hepatitis B (HB) is a preventable disease and a public health challenge due to its high morbidity and mortality. This study was conducted within the framework of the World Health Organization's strategy, which includes establishing prophylactic measures to prevent vertical transmission. The aim was to assess the degree of implementation of HB preventive measures to avoid vertical transmission in newborns in Spain.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A retrospective cross-sectional study was carried out with women who gave birth in 2022 in four autonomous communities in Spain. Clinical databases from primary care, hospitals, vaccination, and microbiology were used. Continuous variables were expressed as the mean and standard deviation or median and interquartile range depending on their distribution. Categorical variables were described by the absolute and relative frequency of each category.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The coverage of hepatitis B screening during pregnancy ranged from 76% to 99.3%, the prevalence of hepatitis B virus infection in pregnant women ranged from 0.23% to 0.60%, and the compliance rate varied between 30.6% and 100%, depending on the autonomous community.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">It is necessary to raise awareness among healthcare professionals to properly record care activities and to improve the interoperability of information systems, screening, and vaccination records to evaluate the implementation of preventive measures against hepatitis B, such as vaccination and immunoglobulin administration.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Veloso Fraigola</LastName><ForeName>Maryoli</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Hospital Universitario Severo Ochoa. Madrid. Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Olmedo Lucer&#xf3;n</LastName><ForeName>Carmen</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>&#xc1;rea de Programas de Vacunaci&#xf3;n. Subdirecci&#xf3;n General de Promoci&#xf3;n de la Salud y Prevenci&#xf3;n. Direcci&#xf3;n General de Salud P&#xfa;blica y Equidad en Salud. Ministerio de Sanidad. Madrid. Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Juaneda</LastName><ForeName>Juan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Direccion General de Salud P&#xfa;blica. Conselleria de Sanidad. Comunidad Valenciana. Valencia. Espa&#xf1;a.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hospital Universitario y Polit&#xe9;cnico La Fe. Valencia. Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lluch Rodrigo</LastName><ForeName>Jos&#xe9; Antonio</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Direccion General de Salud P&#xfa;blica. Conselleria de Sanidad. Comunidad Valenciana. Valencia. Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pastor Villalba</LastName><ForeName>Eliseo</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Direccion General de Salud P&#xfa;blica. Conselleria de Sanidad. Comunidad Valenciana. Valencia. Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tempelsman Mart&#xed;n</LastName><ForeName>Roc&#xed;o</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Direccion General de Salud P&#xfa;blica. Conselleria de Sanidad. Comunidad Valenciana. Valencia. Espa&#xf1;a.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hospital Universitario Doctor Peset. Valencia. Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mart&#xed;nez Marcos</LastName><ForeName>Montserrat</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Miembros Ponencia de Vacunas y/o t&#xe9;cnicos de Programas de Vacunaci&#xf3;n-Catalu&#xf1;a. Barcelona. Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Coma Redon</LastName><ForeName>Ermengol</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Miembros Ponencia de Vacunas y/o t&#xe9;cnicos de Programas de Vacunaci&#xf3;n-Catalu&#xf1;a. Barcelona. Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>P&#xe9;rez Mart&#xed;n</LastName><ForeName>Jaime Jes&#xfa;s</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>Miembros Ponencia de Vacunas y/o t&#xe9;cnicos de Programas de Vacunaci&#xf3;n-Regi&#xf3;n de Murcia. Murcia. Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zornoza Moreno</LastName><ForeName>Matilde</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Miembros Ponencia de Vacunas y/o t&#xe9;cnicos de Programas de Vacunaci&#xf3;n-Regi&#xf3;n de Murcia. Murcia. Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lasheras Carbajo</LastName><ForeName>M&#xaa; Dolores</ForeName><Initials>MD</Initials><AffiliationInfo><Affiliation>Miembros Ponencia de Vacunas y/o t&#xe9;cnicos de Programas de Vacunaci&#xf3;n-Comunidad de Madrid. Madrid. Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Santos Sanz</LastName><ForeName>Sara</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Miembros Ponencia de Vacunas y/o t&#xe9;cnicos de Programas de Vacunaci&#xf3;n-Comunidad de Madrid. Madrid. Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Limia S&#xe1;nchez</LastName><ForeName>Aurora</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>&#xc1;rea de Programas de Vacunaci&#xf3;n. Subdirecci&#xf3;n General de Promoci&#xf3;n de la Salud y Prevenci&#xf3;n. Direcci&#xf3;n General de Salud P&#xfa;blica y Equidad en Salud. Ministerio de Sanidad. Madrid. Espa&#xf1;a.</Affiliation></AffiliationInfo></Author></AuthorList><Language>spa</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Evaluaci&#xf3;n de la vacunaci&#xf3;n frente a la hepatitis B en reci&#xe9;n nacidos con alto riesgo de infecci&#xf3;n por transmisi&#xf3;n vertical.</VernacularTitle><ArticleDate DateType="Electronic"><Year>2024</Year><Month>12</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>Spain</Country><MedlineTA>Rev Esp Salud Publica</MedlineTA><NlmUniqueID>9600212</NlmUniqueID><ISSNLinking>1135-5727</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017325">Hepatitis B Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018445" MajorTopicYN="Y">Infectious Disease Transmission, Vertical</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006509" MajorTopicYN="Y">Hepatitis B</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000635" MajorTopicYN="N">transmission</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017325" MajorTopicYN="Y">Hepatitis B Vaccines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007231" MajorTopicYN="N">Infant, Newborn</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011247" MajorTopicYN="N">Pregnancy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011251" MajorTopicYN="Y">Pregnancy Complications, Infectious</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013030" MajorTopicYN="N" Type="Geographic">Spain</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><OtherAbstract Type="Publisher" Language="spa"><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">La hepatitis B (HB) es una enfermedad prevenible y un reto para la Salud P&#xfa;blica debido a su alta morbilidad y mortalidad. Este estudio se realiz&#xf3; en el marco de la estrategia de la Organizaci&#xf3;n Mundial de la Salud que incluye establecer medidas de profilaxis para evitar la trasmisi&#xf3;n vertical. El objetivo fue evaluar el grado de implementaci&#xf3;n de las medidas preventivas de HB para evitar la transmisi&#xf3;n vertical en reci&#xe9;n nacidos en Espa&#xf1;a.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Se realiz&#xf3; un estudio transversal retrospectivo con las mujeres que dieron a luz en el a&#xf1;o 2022 en cuatro comunidades aut&#xf3;nomas en Espa&#xf1;a. Se utilizaron bases de datos cl&#xed;nicas de Atenci&#xf3;n Primaria, Atenci&#xf3;n Hospitalaria, de vacunaci&#xf3;n y microbiolog&#xed;a. Las variables continuas se expresaron mediante la media y desviaci&#xf3;n est&#xe1;ndar o mediana y rango intercuart&#xed;lico seg&#xfa;n su distribuci&#xf3;n. Las variables categ&#xf3;ricas se describieron mediante la frecuencia absoluta y relativa de cada categor&#xed;a.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">La cobertura del cribado de la hepatitis B en el embarazo oscil&#xf3; entre el 76% y el 99,3%, la prevalencia de infecci&#xf3;n por virus de la hepatitis B en embarazadas oscil&#xf3; entre un 0,23% y un 0,60% ,y el porcentaje de cumplimiento oscil&#xf3; entre el 30,6% y el 100%, seg&#xfa;n comunidad aut&#xf3;noma.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Es necesario concienciar al personal sanitario de la necesidad de registrar la actividad asistencial, as&#xed; como de mejorar la interoperabilidad de los sistemas de informaci&#xf3;n, el registro de cribado y la vacunaci&#xf3;n para evaluar la implementaci&#xf3;n de medidas preventivas frente a hepatitis B, como ser&#xed;an la vacunaci&#xf3;n y la administraci&#xf3;n de inmunoglobulinas.</AbstractText></OtherAbstract><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Evaluation</Keyword><Keyword MajorTopicYN="N">Hepatitis B</Keyword><Keyword MajorTopicYN="N">Newborn</Keyword><Keyword MajorTopicYN="N">Pregnant</Keyword><Keyword MajorTopicYN="N">Spain</Keyword><Keyword MajorTopicYN="N">Vaccination</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>4</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>11</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>12</Month><Day>18</Day><Hour>12</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>12</Month><Day>18</Day><Hour>12</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>12</Month><Day>18</Day><Hour>8</Hour><Minute>23</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39692336</ArticleId><ArticleId IdType="pii">e202412065</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">36681572</PMID><DateCompleted><Year>2024</Year><Month>01</Month><Day>12</Day></DateCompleted><DateRevised><Year>2024</Year><Month>01</Month><Day>12</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2529-993X</ISSN><JournalIssue CitedMedium="Internet"><Volume>41</Volume><Issue>7</Issue><PubDate><Year>2023</Year><Season>Aug-Sep</Season></PubDate></JournalIssue><Title>Enfermedades infecciosas y microbiologia clinica (English ed.)</Title><ISOAbbreviation>Enferm Infecc Microbiol Clin (Engl Ed)</ISOAbbreviation></Journal><ArticleTitle>Efficacy and effectiveness of influenza vaccination in healthy children. A review of current evidence.</ArticleTitle><Pagination><StartPage>396</StartPage><EndPage>406</EndPage><MedlinePgn>396-406</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.eimce.2022.02.016</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2529-993X(23)00008-4</ELocationID><Abstract><AbstractText>Influenza is common in healthy children and adolescents and is associated with a high rate of hospitalization in this group, especially for those &lt;5 years. Although the WHO has recommended vaccination in children under 5 years of age since 2012, it is really implemented in few countries today. The aim of this paper was to review the available evidence on the efficacy/effectiveness of influenza vaccination in healthy children &lt;18 years of age through a non-systematic search of studies conducted between 2010 and 2020. Despite the high variability in results due to differences in design, vaccine type and season included in the 41 selected studies, statistically significant studies show efficacy values for the influenza vaccine of between 25.6% and 74.2%, and effectiveness from 26% to 78.8%. Although a systematic review would be necessary to corroborate the evidence, this review suggests that paediatric vaccination is generally an effective measure for preventing influenza in healthy children in line with international organisms' recommendations.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 The Author(s). Published by Elsevier Espa&#xf1;a, S.L.U. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Orrico-S&#xe1;nchez</LastName><ForeName>Alejandro</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>&#xc1;rea de Investigaci&#xf3;n en vacunas, Fundaci&#xf3;n para el Fomento de la Investigaci&#xf3;n Sanitaria y Biom&#xe9;dica de la Comunidad Valenciana (FISABIO) - Salud P&#xfa;blica, Valencia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Valls-Ar&#xe9;valo</LastName><ForeName>&#xc1;ngel</ForeName><Initials>&#xc1;</Initials><AffiliationInfo><Affiliation>Centro de Salud Nazaret, Departamento Cl&#xed;nico-Malvarrosa, Valencia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garc&#xe9;s-S&#xe1;nchez</LastName><ForeName>Mar&#xed;a</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Centro de Salud Nazaret, Departamento Cl&#xed;nico-Malvarrosa, Valencia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>&#xc1;lvarez Alde&#xe1;n</LastName><ForeName>Javier</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Departamento de Pediatr&#xed;a, Hospital Costa del Sol, M&#xe1;laga, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ortiz de Lejarazu Leonardo</LastName><ForeName>Ra&#xfa;l</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Centro Nacional de Gripe de Valladolid, GISRS (Global Influenza Surveillance and Response System), Valladolid, Spain. Electronic address: lejarazu@gmail.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>01</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>Spain</Country><MedlineTA>Enferm Infecc Microbiol Clin (Engl Ed)</MedlineTA><NlmUniqueID>101777541</NlmUniqueID><ISSNLinking>2529-993X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007252">Influenza Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="N">Hospitalization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007252" MajorTopicYN="Y">Influenza Vaccines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007251" MajorTopicYN="Y">Influenza, Human</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012621" MajorTopicYN="N">Seasons</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Children</Keyword><Keyword MajorTopicYN="N">Efectividad</Keyword><Keyword MajorTopicYN="N">Effectiveness</Keyword><Keyword MajorTopicYN="N">Efficacy</Keyword><Keyword MajorTopicYN="N">Eficacia</Keyword><Keyword MajorTopicYN="N">Gripe</Keyword><Keyword MajorTopicYN="N">Influenza</Keyword><Keyword MajorTopicYN="N">Influenza vaccination</Keyword><Keyword MajorTopicYN="N">Ni&#xf1;os</Keyword><Keyword MajorTopicYN="N">Vacunaci&#xf3;n antigripal</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>10</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>2</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>22</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>21</Day><Hour>22</Hour><Minute>2</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36681572</ArticleId><ArticleId IdType="doi">10.1016/j.eimce.2022.02.016</ArticleId><ArticleId IdType="pii">S2529-993X(23)00008-4</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36496313</PMID><DateCompleted><Year>2023</Year><Month>01</Month><Day>06</Day></DateCompleted><DateRevised><Year>2023</Year><Month>01</Month><Day>11</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2341-2879</ISSN><JournalIssue CitedMedium="Internet"><Volume>98</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Anales de pediatria</Title><ISOAbbreviation>An Pediatr (Engl Ed)</ISOAbbreviation></Journal><ArticleTitle>Vaccination against influenza: Coverage and adherence in children under 15 years with high-risk medical conditions in the Community of Madrid.</ArticleTitle><Pagination><StartPage>3</StartPage><EndPage>11</EndPage><MedlinePgn>3-11</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.anpede.2022.07.006</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2341-2879(22)00223-X</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Vaccination against influenza is indicated in children at risk of complications or severe disease. The objective of this study was to describe the percentage of children aged less than 15 years with risk conditions vaccinated against influenza in the Community of Madrid, and to analyze the factors associated with adherence to vaccination throughout 3 vaccination campaigns.</AbstractText><AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">Population-based cross-sectional observational study of children aged 6 months to 14 years with conditions that indicated influenza vaccination at the beginning of the 2018-2019 campaign. Electronic population registers were used. We described the percentage of children vaccinated in 3 consecutive campaigns, and assessed the association of adherence to vaccination with demographic and socioeconomic variables and risk conditions using bivariate and multivariate analysis.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The vaccination coverage was 15.6% in the 2018-2019 campaign. The adherence to vaccination was 65.9%. The variables associated with greater adherence were age greater than 2 years, especially in the 6-10 years group (aOR&#x202f;=&#x202f;1.63; 95% CI, 1.43-1.85) and presenting more than one risk condition, especially 3 or more diseases (aOR&#x202f;=&#x202f;1.80; 95% CI, 1.00-3.26). Diabetes mellitus was the disease associated most strongly with adherence (aOR&#x202f;=&#x202f;2.15; 95% CI, 1.74-2.65). Adherence was lower in the immigrant population (aOR&#x202f;=&#x202f;0.43; 95% CI, 0.36-0.51). We found no association between vaccination adherence and sex or socioeconomic status.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Vaccination coverage and adherence were suboptimal. Adherence to vaccination against influenza is associated with demographic and clinical conditions. Strategies need to be established to increase vaccination in children, with greater involvement of professionals and education of parents.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 Asociaci&#xf3;n Espa&#xf1;ola de Pediatr&#xed;a. Published by Elsevier Espa&#xf1;a, S.L.U. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>D&#xed;az-Garc&#xed;a</LastName><ForeName>Rosa S</ForeName><Initials>RS</Initials><AffiliationInfo><Affiliation>Servicio de Prevenci&#xf3;n de la Enfermedad, Subdirecci&#xf3;n General de Prevenci&#xf3;n y Promoci&#xf3;n de la Salud, Direcci&#xf3;n General de Salud P&#xfa;blica, Consejer&#xed;a de Sanidad, Comunidad de Madrid, Madrid, Spain; Servicio de Medicina Preventiva y Gesti&#xf3;n de Calidad, Hospital General Universitario Gregorio Mara&#xf1;&#xf3;n, Madrid, Spain. Electronic address: rosoldiga@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>S&#xe1;nchez-G&#xf3;mez</LastName><ForeName>Amaya</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Servicio de Prevenci&#xf3;n de la Enfermedad, Subdirecci&#xf3;n General de Prevenci&#xf3;n y Promoci&#xf3;n de la Salud, Direcci&#xf3;n General de Salud P&#xfa;blica, Consejer&#xed;a de Sanidad, Comunidad de Madrid, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>L&#xf3;pez-Zambrano</LastName><ForeName>Mar&#xed;a Alejandra</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Servicio de Prevenci&#xf3;n de la Enfermedad, Subdirecci&#xf3;n General de Prevenci&#xf3;n y Promoci&#xf3;n de la Salud, Direcci&#xf3;n General de Salud P&#xfa;blica, Consejer&#xed;a de Sanidad, Comunidad de Madrid, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Esteban-Vasallo</LastName><ForeName>Mar&#xed;a Dolores</ForeName><Initials>MD</Initials><AffiliationInfo><Affiliation>Servicio de Informes de Salud y Estudios, Subdirecci&#xf3;n General de Vigilancia en Salud P&#xfa;blica, Direcci&#xf3;n General de Salud P&#xfa;blica, Consejer&#xed;a de Sanidad, Comunidad de Madrid, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ca&#xf1;ellas Llabr&#xe9;s</LastName><ForeName>Soledad</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Servicio de Prevenci&#xf3;n de la Enfermedad, Subdirecci&#xf3;n General de Prevenci&#xf3;n y Promoci&#xf3;n de la Salud, Direcci&#xf3;n General de Salud P&#xfa;blica, Consejer&#xed;a de Sanidad, Comunidad de Madrid, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guti&#xe9;rrez Rodr&#xed;guez</LastName><ForeName>Mar&#xed;a &#xc1;ngeles</ForeName><Initials>M&#xc1;</Initials><AffiliationInfo><Affiliation>Servicio de Prevenci&#xf3;n de la Enfermedad, Subdirecci&#xf3;n General de Prevenci&#xf3;n y Promoci&#xf3;n de la Salud, Direcci&#xf3;n General de Salud P&#xfa;blica, Consejer&#xed;a de Sanidad, Comunidad de Madrid, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lasheras Carbajo</LastName><ForeName>Mar&#xed;a Dolores</ForeName><Initials>MD</Initials><AffiliationInfo><Affiliation>Servicio de Prevenci&#xf3;n de la Enfermedad, Subdirecci&#xf3;n General de Prevenci&#xf3;n y Promoci&#xf3;n de la Salud, Direcci&#xf3;n General de Salud P&#xfa;blica, Consejer&#xed;a de Sanidad, Comunidad de Madrid, Madrid, Spain.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D064888">Observational Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>12</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>Spain</Country><MedlineTA>An Pediatr (Engl Ed)</MedlineTA><NlmUniqueID>101765626</NlmUniqueID><ISSNLinking>2341-2879</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007251" MajorTopicYN="Y">Influenza, Human</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012042" MajorTopicYN="N">Registries</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012923" MajorTopicYN="N">Social Class</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Adolescent</Keyword><Keyword MajorTopicYN="N">Adolescente</Keyword><Keyword MajorTopicYN="N">Child</Keyword><Keyword MajorTopicYN="N">Chronic disease</Keyword><Keyword MajorTopicYN="N">Cobertura de vacunaci&#xf3;n</Keyword><Keyword MajorTopicYN="N">Cross-Sectional studies</Keyword><Keyword MajorTopicYN="N">Cumplimiento y Adherencia al Tratamiento</Keyword><Keyword MajorTopicYN="N">Electronic health records</Keyword><Keyword MajorTopicYN="N">Enfermedad cr&#xf3;nica</Keyword><Keyword MajorTopicYN="N">Espa&#xf1;a</Keyword><Keyword MajorTopicYN="N">Estudios transversales</Keyword><Keyword MajorTopicYN="N">Infancia</Keyword><Keyword MajorTopicYN="N">Infant</Keyword><Keyword MajorTopicYN="N">Influenza vaccines</Keyword><Keyword MajorTopicYN="N">Registros Electr&#xf3;nicos de Salud</Keyword><Keyword MajorTopicYN="N">Spain</Keyword><Keyword MajorTopicYN="N">Treatment adherence and compliance</Keyword><Keyword MajorTopicYN="N">Vaccination coverage</Keyword><Keyword MajorTopicYN="N">Vacuna antigripal</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>3</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>7</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>12</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>12</Month><Day>10</Day><Hour>22</Hour><Minute>5</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36496313</ArticleId><ArticleId IdType="doi">10.1016/j.anpede.2022.07.006</ArticleId><ArticleId IdType="pii">S2341-2879(22)00223-X</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">36456431</PMID><DateRevised><Year>2023</Year><Month>08</Month><Day>03</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2529-993X</ISSN><JournalIssue CitedMedium="Internet"><Volume>41</Volume><Issue>7</Issue><PubDate><Year>2023</Year><Season>Aug-Sep</Season></PubDate></JournalIssue><Title>Enfermedades infecciosas y microbiologia clinica (English ed.)</Title><ISOAbbreviation>Enferm Infecc Microbiol Clin (Engl Ed)</ISOAbbreviation></Journal><ArticleTitle>Adverse events in pregnant women with the tetravalent influenza vaccine obtained from cell cultures.</ArticleTitle><Pagination><StartPage>420</StartPage><EndPage>422</EndPage><MedlinePgn>420-422</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.eimce.2022.11.005</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2529-993X(22)00254-4</ELocationID><Abstract><AbstractText>Influenza vaccination in pregnant women shows a clear benefit/risk ratio. Influenza vaccines are currently being developed using new platforms. It is essential to analyse the safety of these new vaccines in this population group, underrepresented in clinical trials. In the 2019-2020 season, a vaccine obtained in cell culture was recommended to pregnant women in two autonomous communities. Information is collected from the vaccination and pharmacovigilance centres of both communities. The reporting rate of adverse events (AEs) after vaccination in pregnant women was 4.02/100,000 doses administered, and in non-pregnant women aged 18-64 years it was 5.9/100,000 doses administered. The rate of AE reported was 8.04 and 17.74 respectively. No spontaneous abortions, prematurity or foetal malformations were reported. This analysis suggests the safety in pregnant women of the influenza vaccine obtained from cell cultures.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022. Published by Elsevier Espa&#xf1;a, S.L.U.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Carreras</LastName><ForeName>Juan Jos&#xe9;</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>&#xc1;rea de Investigaci&#xf3;n en Vacunas, FISABIO - Salud P&#xfa;blica, Valencia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lluch</LastName><ForeName>Jos&#xe9; Antonio</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Direcci&#xf3;n General de Salud P&#xfa;blica y Adicciones, Conselleria de Sanitat Universal i Salut P&#xfa;blica, Valencia (Comunidad Valenciana), Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Taboada</LastName><ForeName>Jos&#xe9; Antonio</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Programa Galego de Vacinaci&#xf3;n, Direcci&#xf3;n Xeral de Sa&#xfa;de P&#xfa;blica, Conseller&#xed;a de Sanidade, Santiago de Compostela (Galicia), Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pastor-Villalba</LastName><ForeName>Eliseo</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Direcci&#xf3;n General de Salud P&#xfa;blica y Adicciones, Conselleria de Sanitat Universal i Salut P&#xfa;blica, Valencia (Comunidad Valenciana), Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nartallo-Penas</LastName><ForeName>Victoria</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Programa Galego de Vacinaci&#xf3;n, Direcci&#xf3;n Xeral de Sa&#xfa;de P&#xfa;blica, Conseller&#xed;a de Sanidade, Santiago de Compostela (Galicia), Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>D&#xed;ez-Domingo</LastName><ForeName>Javier</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>&#xc1;rea de Investigaci&#xf3;n en Vacunas, FISABIO - Salud P&#xfa;blica, Valencia, Spain. Electronic address: Javier.diez@fisabio.es.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>11</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>Spain</Country><MedlineTA>Enferm Infecc Microbiol Clin (Engl Ed)</MedlineTA><NlmUniqueID>101777541</NlmUniqueID><ISSNLinking>2529-993X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Adverse drug events</Keyword><Keyword MajorTopicYN="N">Adverse drug reaction reporting systems</Keyword><Keyword MajorTopicYN="N">Drug safety</Keyword><Keyword MajorTopicYN="N">Efectos adversos de los medicamentos</Keyword><Keyword MajorTopicYN="N">Farmacoepidemiolog&#xed;a</Keyword><Keyword MajorTopicYN="N">Flu vaccines</Keyword><Keyword MajorTopicYN="N">Pharmacoepidemiology</Keyword><Keyword MajorTopicYN="N">Seguridad de los medicamentos</Keyword><Keyword MajorTopicYN="N">Sistemas de notificaci&#xf3;n de reacciones adversas a los medicamentos</Keyword><Keyword MajorTopicYN="N">Vaccination</Keyword><Keyword MajorTopicYN="N">Vacunaci&#xf3;n</Keyword><Keyword MajorTopicYN="N">Vacunas contra la gripe</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>11</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>2</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>2</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>12</Month><Day>2</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>12</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>12</Month><Day>1</Day><Hour>22</Hour><Minute>8</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36456431</ArticleId><ArticleId IdType="doi">10.1016/j.eimce.2022.11.005</ArticleId><ArticleId IdType="pii">S2529-993X(22)00254-4</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35781154</PMID><DateCompleted><Year>2022</Year><Month>07</Month><Day>07</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1578-1283</ISSN><JournalIssue CitedMedium="Internet"><Volume>36 Suppl 1</Volume><PubDate><Year>2022</Year></PubDate></JournalIssue><Title>Gaceta sanitaria</Title><ISOAbbreviation>Gac Sanit</ISOAbbreviation></Journal><ArticleTitle>[Towards COVID-19 control through vaccination: obstacles, challenges and opportunities. SESPAS Report 2022].</ArticleTitle><Pagination><StartPage>S82</StartPage><EndPage>S86</EndPage><MedlinePgn>S82-S86</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.gaceta.2022.03.002</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0213-9111(22)00098-X</ELocationID><Abstract><AbstractText>In Spain, the vaccination program began in a context of high transmission and low availability of vaccines. The objective of this article is to review the vaccination program against COVID-19 in Europe (3/03/2022) and assess the obstacles, challenges and opportunities posed by the control of this disease. Five vaccines are currently available in Europe: two based on mRNA technology (Comirnaty&#xae; and Spikevax&#xae;); two based on a non-replicative vector (Vaxzevria&#xae; and Janssen); and another based on subunit S (Novavax&#xae;). Health authorities have developed comprehensive vaccination strategies prioritizing the prevention of hospitalizations and deaths. In January 2022, 90% of the population was exceeded with full vaccination and 95% coverage in people over 50 years of age. The new challenge is to achieve similar coverage in the rest of the age groups. Vaccination in children and adolescents has become a priority due to the educational and social implications derived from COVID-19 in this population. Communication strategies must be renewed and access barriers eliminated to achieve good coverage. In Spain, studies have been published that find a high effectiveness of vaccination. The main strategy for controlling the pandemic and recovering social activity is the vaccination, but everything indicates that very high levels of vaccination coverage will be necessary and to follow with the non-pharmaceutical measures. In a globalized world, COVID-19 control will only be achieved with a coordinated global strategy and technical and economic support for the vaccination strategy in resource-poor countries.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 SESPAS. Publicado por Elsevier Espa&#xf1;a, S.L.U. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Godoy</LastName><ForeName>Pere</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Ag&#xe8;ncia de Salut P&#xfa;blica de Catalunya, Barcelona, Espa&#xf1;a; CIBER de Epidemiolog&#xed;a y Salud P&#xfa;blica (CIBERESP), Espa&#xf1;a; Institut de Recerca Biom&#xe8;dica de Lleida (IRBLleida), Lleida, Espa&#xf1;a. Electronic address: pere.godoy@gencat.cat.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Castilla</LastName><ForeName>Jes&#xfa;s</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>CIBER de Epidemiolog&#xed;a y Salud P&#xfa;blica (CIBERESP), Espa&#xf1;a; Instituto de Salud P&#xfa;blica de Navarra-IdiSNA, Pamplona, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Astray</LastName><ForeName>Jenaro</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Direcci&#xf3;n General de Salud P&#xfa;blica, Subdirecci&#xf3;n General de Epidemiolog&#xed;a, Comunidad de Madrid, Madrid, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Godoy</LastName><ForeName>Sof&#xed;a</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Institut Catal&#xe0; de la Salut (ICS), Lleida, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tuells</LastName><ForeName>Jos&#xe9;</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Departamento de Salud P&#xfa;blica, Universidad de Alicante, Alicante, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barrabeig</LastName><ForeName>Irene</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Ag&#xe8;ncia de Salut P&#xfa;blica de Catalunya, Barcelona, Espa&#xf1;a; CIBER de Epidemiolog&#xed;a y Salud P&#xfa;blica (CIBERESP), Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dom&#xed;nguez</LastName><ForeName>&#xc1;ngela</ForeName><Initials>&#xc1;</Initials><AffiliationInfo><Affiliation>CIBER de Epidemiolog&#xed;a y Salud P&#xfa;blica (CIBERESP), Espa&#xf1;a; Departament de Medicina, Universitat de Barcelona, Barcelona, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author></AuthorList><Language>spa</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><VernacularTitle>Hacia el control de la COVID-19 a trav&#xe9;s de la vacunaci&#xf3;n: obst&#xe1;culos, desaf&#xed;os y oportunidades. Informe SESPAS 2022.</VernacularTitle></Article><MedlineJournalInfo><Country>Spain</Country><MedlineTA>Gac Sanit</MedlineTA><NlmUniqueID>8901623</NlmUniqueID><ISSNLinking>0213-9111</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007252">Influenza Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017589" MajorTopicYN="N">Immunization Programs</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007252" MajorTopicYN="Y">Influenza Vaccines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName></MeshHeading></MeshHeadingList><OtherAbstract Type="Publisher" Language="spa"><AbstractText>En Espa&#xf1;a se inici&#xf3; el programa de vacunaci&#xf3;n en un contexto de alta transmisi&#xf3;n y baja disponibilidad de vacunas. El objetivo de este art&#xed;culo es revisar el programa de vacunaci&#xf3;n frente a la COVID-19 (3-3-2022) y valorar los obst&#xe1;culos, los desaf&#xed;os y las oportunidades que plantea el control de esta enfermedad. Se dispone actualmente de cinco vacunas: dos basadas en la tecnolog&#xed;a ARNm (Comirnaty&#xae; y Spikevax&#xae;), dos basadas en un vector no replicativo (Vaxzevria&#xae; y Janssen) y una basada en la subunidad S (Novavax&#xae;). Las autoridades sanitarias han desarrollado estrategias de vacunaci&#xf3;n priorizando la prevenci&#xf3;n de hospitalizaciones y defunciones. En marzo de 2022 se super&#xf3; el 90% de la poblaci&#xf3;n diana con vacunaci&#xf3;n completa y el 95% de cobertura en mayores de 50 a&#xf1;os. El nuevo reto es conseguir coberturas similares para una tercera dosis. La vacunaci&#xf3;n en la infancia y la adolescencia se ha convertido en una prioridad por las implicaciones educativas y sociales que comporta la COVID-19. Se deber&#xe1;n renovar las estrategias comunicativas y eliminar las barreras de acceso para conseguir buenas coberturas. En Espa&#xf1;a se han publicado estudios que muestran una alta efectividad de la vacunaci&#xf3;n. La principal estrategia para el control de la pandemia y para recuperar la actividad social es la vacunaci&#xf3;n, pero todo indica que ser&#xe1;n necesarios niveles muy altos de cobertura vacunal y seguir con medidas no farmacol&#xf3;gicas. En un mundo globalizado, el control de la COVID-19 solo se alcanzar&#xe1; con una estrategia global coordinada y el apoyo a la vacunaci&#xf3;n en los pa&#xed;ses con pocos recursos.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 SESPAS. Publicado por Elsevier Espa&#xf1;a, S.L.U. All rights reserved.</CopyrightInformation></OtherAbstract><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Epidemiology</Keyword><Keyword MajorTopicYN="N">Epidemiolog&#xed;a</Keyword><Keyword MajorTopicYN="N">Evaluaci&#xf3;n</Keyword><Keyword MajorTopicYN="N">Evaluation study</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">Vaccines</Keyword><Keyword MajorTopicYN="N">Vacunas</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>8</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>3</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>3</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>7</Month><Day>5</Day><Hour>8</Hour><Minute>51</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>7</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>7</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>6</Month><Day>30</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35781154</ArticleId><ArticleId IdType="pmc">PMC9244662</ArticleId><ArticleId IdType="doi">10.1016/j.gaceta.2022.03.002</ArticleId><ArticleId IdType="pii">S0213-9111(22)00098-X</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>The Financial Times. Covid vaccine development: the shots available and the doses administered. The Financial Times; 2021. (Consultado el 20-11-2021.) Disponible en: https://www.ft.com/content/ac5e5ef8-bccb-482b-9f8d-0dab5cac6f9a].</Citation></Reference><Reference><Citation>Katz I.T., Weintraub R., Bekker L.G., et al. From vaccine nationalism to vaccine equity &#x2014; finding a path forward. N Engl J Med. 2021;384:1281&#x2013;1283.</Citation><ArticleIdList><ArticleId IdType="pubmed">33830709</ArticleId></ArticleIdList></Reference><Reference><Citation>Eccleston-Turner M., Upton H. International collaboration to ensure equitable access to vaccines for COVID-19: the ACT-Accelerator and the COVAX facility. Milbank Q. 2021;99:426&#x2013;449.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8014072</ArticleId><ArticleId IdType="pubmed">33650737</ArticleId></ArticleIdList></Reference><Reference><Citation>Usher A.D. A beautiful idea: how COVAX has fallen short. Lancet. 2021;397:2322&#x2013;2325.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8494620</ArticleId><ArticleId IdType="pubmed">34147145</ArticleId></ArticleIdList></Reference><Reference><Citation>Grupo de trabajo t&#xe9;cnico de vacunaci&#xf3;n COVID-19 de la Ponencia de Programa y Registro de Vacunaciones. Actualizaci&#xf3;n 6. Estrategia de vacunaci&#xf3;n frente a COVID-19 en Espa&#xf1;a. Madrid: Ministerio de Sanidad, Gobierno de Espa&#xf1;a; 2021. p. 1-26. Disponible en: https://www.mscbs.gob.es/profesionales/saludPublica/prevPromocion/vacunaciones/covid19/docs/COVID-19_Actualizacion8_EstrategiaVacunacion.pdf.</Citation></Reference><Reference><Citation>Centro de Coordinaci&#xf3;n de Alertas Sanitarias y Emergencias. Informaci&#xf3;n T&#xe9;cnico Sanitaria. Informaci&#xf3;n sobre la inmunidad y el desarrollo de vacunas frente a COVID-19. Madrid: Ministerio de Sanidad, Secretar&#xed;a de Estado de Sanidad; 2021. p. 1-33.</Citation></Reference><Reference><Citation>European Medicines Agency. COVID-19 vaccines: authorised. EMA; 2021. (Consultado el 15-8-2021.) Disponible en: https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/coronavirus-disease-covid-19/treatments-vaccines/vaccines-covid-19/covid-19-vaccines-authorised#covid-19-vaccines-section.</Citation></Reference><Reference><Citation>European Medicines Agency. Vaxzevria (previously COVID-19 Vaccine AstraZeneca). EMA; 2021. (Consultado el 15-8-2021.) Disponible en: https://www.ema.europa.eu/en/medicines/human/EPAR/vaxzevria-previously-covid-19-vaccine-astrazeneca.</Citation></Reference><Reference><Citation>European Medicines Agency. Comirnaty. EMA; 2021. (Consultado el 15-8-2021.) Disponible en: https://www.ema.europa.eu/en/medicines/human/EPAR/comirnaty.</Citation></Reference><Reference><Citation>European Medicines Agency. Spikevax (previously COVID-19 Vaccine Moderna). EMA; 2021. (Consultado el 15-8-2021.) Disponible en: https://www.ema.europa.eu/en/medicines/human/EPAR/spikevax-previously-covid-19-vaccine-moderna.</Citation></Reference><Reference><Citation>Grupo de trabajo t&#xe9;cnico de vacunaci&#xf3;n COVID-19 de la Ponencia de Programa y Registro de Vacunaciones. Vacunaciones. Madrid: Ministerio de Sanidad, Gobierno de Espa&#xf1;a; 2021. p. 1-36. Disponible en: https://www.mscbs.gob.es/profesionales/saludPublica/prevPromocion/vacunaciones/covid19/docs/COVID-19_Actualizacion4_EstrategiaVacunacion.pdf.</Citation></Reference><Reference><Citation>Borobia A.M., Carcas A.J., P&#xe9;rez-Olmeda M., et al. Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial. Lancet. 2021;398:582.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8233007</ArticleId><ArticleId IdType="pubmed">34181880</ArticleId></ArticleIdList></Reference><Reference><Citation>Ministerio de Sanidad. Estrategia de vacunaci&#xf3;n COVID-19 en Espa&#xf1;a. L&#xed;neas maestras. 2020. p. 1-18. Disponible en: https://www.sanidad.gob.es/gabinetePrensa/notaPrensa/pdf/24.11241120144431769.pdf</Citation></Reference><Reference><Citation>European Centre for Disease Prevention and Control. Overview of COVID-19 vaccination strategies and vaccine deployment plans in the EU/EEA and the UK. Stockholm: ECD; 2020. p. 1-22. Disponible en: https://www.ecdc.europa.eu/en/publications-data/overview-current-eu-eea-uk-plans-covid-19-vaccines.</Citation></Reference><Reference><Citation>Castilla J., Guevara M., Miqueleiz A., et al. Risk factors of infection, hospitalization and death from SARS-CoV-2: a population-based cohort study. J Clin Med. 2021;10:2608.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8231921</ArticleId><ArticleId IdType="pubmed">34199198</ArticleId></ArticleIdList></Reference><Reference><Citation>European Centre for Disease Prevention and Control. COVID-19 vaccination and prioritisation strategies in the EU/EEA. Stockholm: ECDC; 2020. p. 1-20. Disponible en: https://www.ecdc.europa.eu/en/publications-data/covid-19-vaccination-and-prioritisation-strategies-eueea.</Citation></Reference><Reference><Citation>Mart&#xed;nez-Baz I., Miqueleiz A., Casado I., et al. Effectiveness of COVID-19 vaccines in preventing SARS-CoV-2 infection and hospitalisation, Navarre, Spain. January to April 2021. Eurosurveillance. 2021;26:1&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8161727</ArticleId><ArticleId IdType="pubmed">34047271</ArticleId></ArticleIdList></Reference><Reference><Citation>Ministerio de Sanidad. GIV COVID-19. Informe de actividad de la vacunaci&#xf3;n, 2021. (Consultado el 14-8-2021.) Disponible en: https://www.mscbs.gob.es/profesionales/saludPublica/ccayes/alertasActual/nCov/documentos/Informe_GIV_comunicacion_20210823.pdf.</Citation></Reference><Reference><Citation>World Health Organization. Evaluation of COVID-19 vaccine effectiveness. Geneva: WHO; 2021. p. 70. Disponible en: WHO/2019-nCoV/vaccine_effectiveness/measurement/2021.1.</Citation></Reference><Reference><Citation>Hodgson S.H., Mansatta K., Mallett G., et al. What defines an efficacious COVID-19 vaccine?. A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2. Lancet Infect Dis. 2021;21:e26&#x2013;e35.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7837315</ArticleId><ArticleId IdType="pubmed">33125914</ArticleId></ArticleIdList></Reference><Reference><Citation>L&#xf3;pez Bernal J., Andrews N., Gower C., et al. Effectiveness of Covid-19 vaccines against the B.1.617.2 (Delta) variant. N Engl J Med. 2021;385:585&#x2013;594.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8314739</ArticleId><ArticleId IdType="pubmed">34289274</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernal J.L., Andrews N., Gower C., et al. Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study. BMJ. 2021;373:1088.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8116636</ArticleId><ArticleId IdType="pubmed">33985964</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown C.M., Vostok J., Johnson H., et al. Outbreak of SARS-CoV-2 infections, including COVID-19 vaccine breakthrough infections, associated with large public gatherings. MMWR Morb Mortal Wkly Rep. 2021;70:1&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8367314</ArticleId><ArticleId IdType="pubmed">34351882</ArticleId></ArticleIdList></Reference><Reference><Citation>Keehner J., Horton L.E., Pfeffer M.A., et al. SARS-CoV-2 infection after vaccination in health care workers in California. N Engl J Med. 2021;384:1774&#x2013;1775.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8008750</ArticleId><ArticleId IdType="pubmed">33755376</ArticleId></ArticleIdList></Reference><Reference><Citation>Swift M.D., Breeher L.E., Tande A.J., et al. Effectiveness of messenger RNA coronavirus disease 2019 (COVID-19) vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in a cohort of healthcare personnel. Clin Infect Dis. 2021;76:e1376&#x2013;e1379.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8135611</ArticleId><ArticleId IdType="pubmed">33900384</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson M.G., Burgess J.L., Naleway A.L., et al. Interim estimates of vaccine effectiveness of BNT162b2 and mRNA-1273 COVID-19 vaccines in preventing SARS-CoV-2 infection among health care personnel, first responders, and other essential and frontline workers &#x2014; eight U.S. locations, December 2020&#x2013;March. MMWR Morb Mortal Wkly Rep. 2021;70:495&#x2013;500.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8022879</ArticleId><ArticleId IdType="pubmed">33793460</ArticleId></ArticleIdList></Reference><Reference><Citation>Korang S.K., von Rohden E., Veroniki A.A., et al. Vaccines to prevent COVID-19: a living systematic review with trial sequential analysis and network meta-analysis of randomized clinical trials. PLoS One. 2022;17:1&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8782520</ArticleId><ArticleId IdType="pubmed">35061702</ArticleId></ArticleIdList></Reference><Reference><Citation>Rotshild V., Hirsh-Raccah B., Miskin I., et al. Comparing the clinical efficacy of COVID-19 vaccines: a systematic review and network meta-analysis. Sci Rep. 2021;11:1&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8611039</ArticleId><ArticleId IdType="pubmed">34815503</ArticleId></ArticleIdList></Reference><Reference><Citation>Grupo de trabajo de efectividad de la vacunaci&#xf3;n COVID-19. Ministerio de Sanidad, Gobierno de Espa&#xf1;a. An&#xe1;lisis de la efectividad y el impacto de la vacunaci&#xf3;n frente a COVID-19 en residentes de centros de mayores en Espa&#xf1;a. 2021. p. 1-18. Disponible en: https://www.mscbs.gob.es/profesionales/saludPublica/prevPromocion/vacunaciones/covid19/docs/Efectividad_Residentes_Centros_Mayores_Informe.pdf.</Citation></Reference><Reference><Citation>Monge S., Olmedo C., Alejos B., et al. Direct and indirect effectiveness of mRNA vaccination against SARS-CoV-2 infection in long-term care facilities in Spain. medRxiv. 2021 2021.04.08.21255055.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8462307</ArticleId><ArticleId IdType="pubmed">34314670</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodr&#xed;guez Y., Novelli L., Rojas M., et al. Autoinflammatory and autoimmune conditions at the crossroad of COVID-19. J Autoimmun. 2020;114:102506.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7296326</ArticleId><ArticleId IdType="pubmed">32563547</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenblum H.G., Hadler S.C., Moulia D., et al. Use of COVID-19 vaccines after reports of adverse events among adult recipients of Janssen (Johnson &amp; Johnson) and mRNA COVID-19 Vaccines (Pfizer-BioNTech and Moderna): update from the Advisory Committee on Immunization Practices &#x2014; United States. July 202. MMWR Morb Mortal Wkly Rep. 2021;70:1094&#x2013;1099.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8360272</ArticleId><ArticleId IdType="pubmed">34383735</ArticleId></ArticleIdList></Reference><Reference><Citation>Products, Medicines and Healthcare Regulatory Agency. Coronavirus vaccine. Summary of yellow card reporting. 2021. (Consultado el 14-8-2021.) Disponible en: https://www.gov.uk/government/publications/coronavirus-covid-19-vaccine-adverse-reactions/coronavirus-vaccine-summary-of-yellow-card-reporting.</Citation></Reference><Reference><Citation>Instituto de Salud Carlos III. El uso combinado de las vacunas de AstraZeneca y Pfizer contra el SARS-CoV-2 ofrece una potente respuesta inmunitaria. ISCIII; 2021. Disponible en: https://www.isciii.es/Noticias/Noticias/Paginas/Noticias/Presentaci&#xf3;n-resultados-preliminares-CombivacS.aspx.</Citation></Reference><Reference><Citation>Normark J., Vikstr&#xf6;m L., Gwon Y., et al. Heterologous ChAdOx1 nCoV-19 and mRNA-1273 vaccination. N Engl J Med. 2021;385:1&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8314734</ArticleId><ArticleId IdType="pubmed">34260850</ArticleId></ArticleIdList></Reference><Reference><Citation>Atmar R.L., Lyke K.E., Deming M.E., et al. Homologous and heterologous Covid-19 booster vaccinations. N Engl J Med. 2022;386:1046&#x2013;1057.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8820244</ArticleId><ArticleId IdType="pubmed">35081293</ArticleId></ArticleIdList></Reference><Reference><Citation>Centers for Disease Control and Prevention. COVID-19 vaccine booster shots. CDC; 2021. (Consultado el 20-11-2021.) Disponible en: https://www.cdc.gov/coronavirus/2019-ncov/vaccines/booster-shot.html.</Citation></Reference><Reference><Citation>Kavanagh M.M., Gostin L.O., Sunder M. Restoring vaccine diplomacy. JAMA. 2021;326:219&#x2013;220.</Citation><ArticleIdList><ArticleId IdType="pubmed">34196659</ArticleId></ArticleIdList></Reference><Reference><Citation>Binagwaho A., Mathewos K., Davis S. Time for the ethical management of COVID-19 vaccines. Lancet Glob Health. 2021;9:e1169&#x2013;e1171.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8096324</ArticleId><ArticleId IdType="pubmed">33961810</ArticleId></ArticleIdList></Reference><Reference><Citation>Moon S., Ruiz A.A., Vieira M. Averting future vaccine injustice. N Engl J Med. 2021;385:193&#x2013;196.</Citation><ArticleIdList><ArticleId IdType="pubmed">34265190</ArticleId></ArticleIdList></Reference><Reference><Citation>Krause P.R., FlemingTR, Longini I.M., et al. SARS-CoV-2 variants and vaccines. N Engl J Med. 2021;385:179&#x2013;186.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8262623</ArticleId><ArticleId IdType="pubmed">34161052</ArticleId></ArticleIdList></Reference><Reference><Citation>Schaefer G., Leland R., Emanuel E. Making vaccines available to other countries before offering domestic booster vaccinations. JAMA. 2021;326:903&#x2013;904.</Citation><ArticleIdList><ArticleId IdType="pubmed">34382999</ArticleId></ArticleIdList></Reference><Reference><Citation>Chinn J., Sedighim S., Kirby K.A., et al. Characteristics and outcomes of women with COVID-19 giving birth at US academic centers during the COVID-19 pandemic. JAMA Netw Open. 2021;4:e2120456.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8358731</ArticleId><ArticleId IdType="pubmed">34379123</ArticleId></ArticleIdList></Reference><Reference><Citation>Pratama N.R., Wafa I.A., Budi D.S., et al. mRNA Covid-19 vaccines in pregnancy: a systematic review. PLoS One. 2022;17:e0261350.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8809595</ArticleId><ArticleId IdType="pubmed">35108277</ArticleId></ArticleIdList></Reference><Reference><Citation>Frenck R.W., Klein N.P., Kitchin N., et al. Safety, immunogenicity, and efficacy of the BNT162b2 Covid-19 vaccine in adolescents. N Engl J Med. 2021;385:239&#x2013;250.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8174030</ArticleId><ArticleId IdType="pubmed">34043894</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C., Huang L., Wang Y., et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet. 2021;397:220&#x2013;232.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7833295</ArticleId><ArticleId IdType="pubmed">33428867</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization. A clinical case definition of post COVID-19 condition by a Delphi consensus. WHO; 2021. Disponible en: https://www.who.int/publications/i/item/WHO-2019-nCoV-Post_COVID-19_condition-Clinical_case_definition-2021.1.</Citation></Reference><Reference><Citation>Arnold D.T., Milne A., Stadon L., et al. Symptoms after COVID-19 vaccination in patients with persistent symptoms after acute infection: a case series. Ann Intern Med. 2021;172:1&#x2013;2.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8252827</ArticleId><ArticleId IdType="pubmed">34029484</ArticleId></ArticleIdList></Reference><Reference><Citation>Sherwood O., Strain W.D. The impact of COVID vaccination on symptoms of long Covid. An international survey of 900 people with lived experience. LongCovidSOS; 2021 Disponible en: https://3ca26cd7-266e-4609-b25f-6f3d1497c4cf.filesusr.com/ugd/8bd4fe_a338597f76bf4279a851a7a4cb0e0a74.pdf.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9146071</ArticleId><ArticleId IdType="pubmed">35632408</ArticleId></ArticleIdList></Reference><Reference><Citation>Centers for Disease Control and Prevention. Interim clinical considerations for use of COVID-19 vaccines currently authorized in the United States. Disponible en: https://www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html.</Citation></Reference><Reference><Citation>Macintyre C.R., Costantino V., Trent M. Modelling of COVID-19 vaccination strategies and herd immunity, in scenarios of limited and full vaccine supply in NSW, Australia. Vaccine. 2021 Apr 24;S0264&#x2013;410X:00501&#x2013;506. doi: 10.1016/j.vaccine.2021.04.042. Online ahead of print.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2021.04.042</ArticleId><ArticleId IdType="pmc">PMC8064825</ArticleId><ArticleId IdType="pubmed">33958223</ArticleId></ArticleIdList></Reference><Reference><Citation>Mart&#xed;nez-Baz I., Trobajo-Sanmart&#xed;n C., Miqueleiz A., et al. Product-specific COVID-19 vaccine effectiveness against secondary infection in close contacts, Navarre, Spain. April to August 2021. Euro Surveill. 2021;26:1&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8485582</ArticleId><ArticleId IdType="pubmed">34596016</ArticleId></ArticleIdList></Reference><Reference><Citation>Murray C.J.L. COVID-19 will continue but the end of the pandemic is near. Lancet. 2022;6736:417&#x2013;419.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8769657</ArticleId><ArticleId IdType="pubmed">35065006</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35179148</PMID><DateCompleted><Year>2022</Year><Month>02</Month><Day>21</Day></DateCompleted><DateRevised><Year>2022</Year><Month>02</Month><Day>21</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2173-9110</ISSN><JournalIssue CitedMedium="Internet"><Volume>96</Volume><PubDate><Year>2022</Year><Month>Feb</Month><Day>16</Day></PubDate></JournalIssue><Title>Revista espanola de salud publica</Title><ISOAbbreviation>Rev Esp Salud Publica</ISOAbbreviation></Journal><ArticleTitle>[Predictions of three mathematical models related with the COVID-19 Vaccination Strategy in Spain. June 2021.].</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">e202202019</ELocationID><Abstract><AbstractText>The Ministry of Health has coordinated three studies that have estimated the impact of the COVID-19 Vaccination Strategy in Spain. The models aim to help how to establish priority population groups for vaccination, in an initial context of dose limitation. With the same epidemiological and vaccine information, the results of this three different mathematical models point in the same direction: combined with physical distancing, staggered vaccination, starting with the high risk groups, would prevent 60% of infections, 42% of hospitalizations and 60% of mortality in the population. These models, which can be adapted to the new available scientific evidence, are dynamic and powerful tools for the evaluation and adjustment of immunization programs, promoting research on this field, and helping to achieve more efficient results in health.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Olmedo Lucer&#xf3;n</LastName><ForeName>Carmen</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>&#xc1;rea de Vacunas. Subdirecci&#xf3;n General de Promoci&#xf3;n de la Salud y Prevenci&#xf3;n. Direcci&#xf3;n General de Salud P&#xfa;blica. Ministerio de Sanidad. Madrid. Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>D&#xed;ez Domingo</LastName><ForeName>Javier</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Fundaci&#xf3;n para el Fomento de la Investigaci&#xf3;n Sanitaria y Biom&#xe9;dica de la Comunidad Valenciana (Fisabio). Valencia. Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Exp&#xf3;sito Singh</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Universidad Carlos III de Madrid. Madrid. Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mori&#xf1;a Soler</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Universidad de Barcelona. Barcelona. Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aznarte</LastName><ForeName>Jos&#xe9; Luis</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Universidad Nacional de Educaci&#xf3;n a Distancia (UNED). Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Almagro Pedre&#xf1;o</LastName><ForeName>Jos&#xe9;</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Inverence. Madrid. Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Limia S&#xe1;nchez</LastName><ForeName>Aurora</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>&#xc1;rea de Vacunas. Subdirecci&#xf3;n General de Promoci&#xf3;n de la Salud y Prevenci&#xf3;n. Direcci&#xf3;n General de Salud P&#xfa;blica. Ministerio de Sanidad. Madrid. Espa&#xf1;a.</Affiliation></AffiliationInfo></Author></AuthorList><Language>spa</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Predicciones de tres modelos matem&#xe1;ticos en relaci&#xf3;n a la estrategia de vacunaci&#xf3;n frente a la COVID-19 en Espa&#xf1;a. Junio de 2021.</VernacularTitle><ArticleDate DateType="Electronic"><Year>2022</Year><Month>02</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>Spain</Country><MedlineTA>Rev Esp Salud Publica</MedlineTA><NlmUniqueID>9600212</NlmUniqueID><ISSNLinking>1135-5727</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="Y">COVID-19 Vaccines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008962" MajorTopicYN="N">Models, Theoretical</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013030" MajorTopicYN="N" Type="Geographic">Spain</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName></MeshHeading></MeshHeadingList><OtherAbstract Type="Publisher" Language="spa"><AbstractText>El Ministerio de Sanidad ha coordinado tres estudios que han estimado el impacto de la Estrategia de Vacunaci&#xf3;n frente a COVID-19 en Espa&#xf1;a. El objetivo era que los modelos ayudaran a establecer los grupos de poblaci&#xf3;n prioritarios para la vacunaci&#xf3;n, en un contexto inicial de limitaci&#xf3;n de dosis. A partir de la misma informaci&#xf3;n epidemiol&#xf3;gica y de vacunas se han elaborado tres modelos matem&#xe1;ticos distintos cuyos resultados apuntan en la misma direcci&#xf3;n: combinada con el distanciamiento f&#xed;sico, la vacunaci&#xf3;n escalonada, empezando por los grupos de mayor riesgo de complicaciones, evitar&#xed;a el 60% de las infecciones, el 42% de las hospitalizaciones y el 60% de la mortalidad en la poblaci&#xf3;n. Estos modelos, que pueden adaptarse a la nueva evidencia cient&#xed;fica disponible, son herramientas din&#xe1;micas y potentes para la evaluaci&#xf3;n y el ajuste de los programas de vacunaci&#xf3;n, impulsando el desarrollo de este campo de investigaci&#xf3;n, y ayudando a lograr resultados m&#xe1;s eficientes en salud.</AbstractText></OtherAbstract><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Immunization programmes</Keyword><Keyword MajorTopicYN="N">Mathematical modeling</Keyword><Keyword MajorTopicYN="N">Spain</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>11</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>1</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>2</Month><Day>18</Day><Hour>8</Hour><Minute>40</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>2</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>2</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35179148</ArticleId><ArticleId IdType="pii">e202202019</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>